Impact News +++ Monro outlines $25M-$35M fiscal 2027 capex while starting broad strategic alternatives review (SeekingAlpha) +++ MONRO Aktie -4,81%

OPKO HEALTH Aktie

>OPKO HEALTH Aktienkurs

1.1 EUR -0.9% (TradegateBSX)

Ask: 1.1 EUR / 9100 Stück

Bid: 1.09 EUR / 9300 Stück

Tagesumsatz: 13048 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OPKO HEALTH Aktie über LYNX handeln

Intraday

1 Jahr

>OPKO HEALTH Performance

1 Woche: +11,1%

1 Monat: +5,7%

3 Monate: +11,0%

6 Monate: -4,7%

1 Jahr: -1,2%

laufendes Jahr: +0,4%

>OPKO HEALTH Aktie

Name:

OPKO HEALTH INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US68375N1037 / A0MUUJ

Symbol/ Ticker:

XCY (Frankfurt) / OPK (NASDAQ)

Kürzel:

FRA:XCY, ETR:XCY, XCY:GR, NASDAQ:OPK

Index:

Webseite:

https://www.opko.com/

Profil:

OpKO Health Inc. is a multinational biopharmaceutical and diagnostics company operating through two primary segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, it develops and commercializes therapies such as Rayaldee, FDA-appr..
>Volltext..

Marktkapitalisierung:

823.9 Mio. EUR

Unternehmenswert:

871.54 Mio. EUR

Umsatz:

499.27 Mio. EUR

EBITDA:

-96.65 Mio. EUR

Nettogewinn:

-182.93 Mio. EUR

Gewinn je Aktie:

-0.24 EUR

Schulden:

341.02 Mio. EUR

Liquide Mittel:

293.73 Mio. EUR

Operativer Cashflow:

Bargeldquote:

2.3

Umsatzwachstum:

-21.07%

Gewinnwachstum:

-410.83%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OPKO HEALTH

Letzte Datenerhebung:

27.05.26

>OPKO HEALTH Kennzahlen

Aktien/ Unternehmen:

Aktien: 755.09 Mio. St.

Frei handelbar: 49.97%

Leerverk. Aktien: 4.47%

Rückkaufquote: 5.44%

Mitarbeiter: 2275

Umsatz/Mitarb.: 0.23 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 198.2%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.57

KBV: 0.78

PEG-Ratio: -0.02

EV/EBITDA: -

Rentabilität:

Bruttomarge: 22.73%

Gewinnmarge: -36.64%

Operative Marge: -34.9%

Managementeffizenz:

Gesamtkaprendite: -10.69%

Eigenkaprendite: -16.92%

>OPKO HEALTH Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Nierenerkrankungen & -behandlung

>OPKO HEALTH Chart & Kurs - NASDAQ

>OPKO HEALTH News

21.05.26 - 19:45	Here′s Why You Should Retain OPK Stock in Your Portfolio for Now (Zacks)
	OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven....

30.04.26 - 14:33	OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China (GlobeNewswire EN)
	Grants OPKO a 15% equity interest in Nicoya Grants OPKO a 15% equity interest in Nicoya...

30.04.26 - 14:03	BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform (GlobeNewswire EN)
	ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing....

29.04.26 - 20:30	OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y (Zacks)
	OPK's Q1 earnings match estimates as pharma product sales rose, but revenue slides 25.7% after a smaller BioReference diagnostics base....

29.04.26 - 02:30	OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	OPKO Health (OPK) delivered earnings and revenue surprises of -2.94% and -4.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

29.04.26 - 02:30	OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
	Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

29.04.26 - 00:06	OPKO Health im Q1 2026: Umsatzrückgang und verfehlte Prognosen belasten die Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

28.04.26 - 22:09	OPKO Health GAAP EPS of -$0.07 in-line, revenue of $124.2M misses by $6.57M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.04.26 - 22:09	OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire EN)
	Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today...

27.04.26 - 23:36	OPKO Health Q1 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 19:45	Here′s Why You Should Hold OPK Stock in Your Portfolio for Now (Zacks)
	OPKO Health rides on RAYALDEE strength, partnerships and restructuring gains, but reliance on a single drug keeps risk in focus for investors....

22.04.26 - 14:03	OPKO Health′s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas (GlobeNewswire EN)
	Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas...

21.04.26 - 22:09

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire EN)

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time....

08.04.26 - 14:03	OPKO Health′s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 (GlobeNewswire EN)
	Subjects dosed in Phase 1 study evaluating safety and tolerability of a first-in-class multispecific antibody Subjects dosed in Phase 1 study evaluating safety and tolerability of a first-in-class multispecific antibody...

21.03.26 - 01:01	Insiderhandel: Aufsichtsrat kauft Aktien von Opko Health im Wert von 11350 USD (Insiderkauf)
	Paganelli, John A. - Aufsichtsrat - Tag der Transaktion: 2026-03-20...

27.02.26 - 20:31	OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts (Zacks)
	OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows....

27.02.26 - 14:03	OPKO Health to Participate in the Jefferies Biotech on the Beach Summit (GlobeNewswire EN)
	MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th....

27.02.26 - 03:00	OPKO Health (OPK) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 02:30	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	OPKO Health (OPK) delivered earnings and revenue surprises of +39.39% and +7.56%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

27.02.26 - 02:30	Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics (Zacks)
	While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: O, der Einfall war kindisch, aber göttlich schön! - Friedrich Johann Christoph Schiller

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram